Project Details
Description
In this STTR Phase I application, the Hu laboratory at UTMB partners with the biotech startup company, RNA Therapeutics Inc, to submit a proposal that aims to further develop a panCOVID-19 mRNA vaccine candidate. The work to be conducted at UTMB include animal (hamster) vaccination and SARS-CoV-2 challenge to evaluate protective efficacy of the vaccines in animal models.
| Status | Active |
|---|---|
| Effective start/end date | 3/13/24 → 2/28/25 |
Funding
- RNA Therapeutics, Inc ( Award #1R41AI18113401): $145,535.59
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.